

# 1 Serological evidence of dengue fever and associated factors in health facilities 2 in Borena Zone, Southern Ethiopia

3 Eshetu Nigussie Geleta

4 Department of Medical Laboratory Science, Madda Walabu University, Bale Goba,  
5 Ethiopia.

6 [eshetunba@gmail.com](mailto:eshetunba@gmail.com)

## 7 Abstract

8 **Background:** Dengue fever is a re-emerging public health threat in Ethiopia. Yet, little is  
9 known about the epidemiology and risk factors. In this study the seroprevalence and associated  
10 risk factors of dengue virus infection were assessed in Borena Zone health facilities.

11 **Methods:** An institution based cross-sectional study was conducted from May to August, 2016.  
12 A total of 519 consecutive acute febrile patients attending the outpatient departments of Teltelle  
13 health Center, Yabello and Moyale Hospital were enrolled. Data on socio-demographic and  
14 environmental risk factors were collected using structured questionnaire. Three to five milliliter  
15 blood samples were collected from all participants and screened for dengue virus exposure using  
16 indirect immunofluorescent assay.

17 **Result:** The overall prevalence of anti-DENV IgG and IgM was 22.9% and 7.9% respectively.  
18 The relatively higher IgM versus IgG, absence of trend with age and little or no correlation with  
19 the assessed possible risk factors except being male (AOR=1.72; 95%CI 1.01-2.94), place of  
20 residence (AOR=0.37;95%CL 0.21-0.64) that had higher rate of exposure and recall of a recent  
21 mosquito bite (AOR=2.98; 95%CI 1.51-5.89) probably imply recent and/or ongoing active  
22 transmission.

23 **Conclusion:** This study showed dengue fever could potentially emerge as public health threat in  
24 the study area. On top, the observed low awareness of participants underline the urgent need for  
25 further systematic studies to determine the environmental, and host factors that determine the  
26 extent of exposure to dengue virus infection in the area for appropriate control and prevention  
27 planning.

28 **Key words:** Borena, Dengue Virus, Indirect Immunofluorescent Assay, Ethiopia

## 29 **Author summary**

30 Dengue fever is a mosquito-borne viral disease of global health problem where *Aedes aegypti*  
31 mosquitoes are the main vector. It is endemic in most tropical and sub-tropical countries with an  
32 estimated 96 million infections resulting in clinical disease annually. It is unrecognized and  
33 underreported in Africa, particularly in Ethiopia. So, the current study were conducted among  
34 febrile patients who were attending health institutions to document seroprevalence and  
35 associated risk factors of DENV infection in the southern part of the country. The study stated  
36 the presence of antibodies against DENV infection in study areas, the ringing bell message for  
37 those who were involved in health sectors. Gender and residence were significantly associated  
38 with the prevalence of anti-DENV IgG seropositivity. In addition, individuals who have  
39 experience of recent mosquito bite were identified as the risk factors of DENV infection.  
40 Therefore, I recommend that preventive measures should be considered and nationwide  
41 surveillance should be carried out at nationwide.

## 42 **Introduction**

43 Dengue fever (DF) is the most rapidly spreading mosquito-borne disease and the major public  
44 health problem on the world [1]. Dengue is a viral disease caused by dengue virus serotypes  
45 (DENV1-4) of the genus Flavivirus. Dengue virus is a non-segmented, positive-sense, single-  
46 stranded, enveloped RNA virus; transmitted primarily by the bite of *Aedes aegypti* and *Aedes*  
47 *albopictus* [2, 3]. Infections can also be transmitted through blood transfusion, organ  
48 transplantation and possibly vertically from mother to child [4, 5]. The virus distributed in more  
49 than 100 countries in tropical and subtropical areas; across the Americas, East Mediterranean,  
50 Western Pacific, Africa, South-East Asia and Europe [6]. The dengue infection has been  
51 reported in most African countries, especially in Eastern Africa including Ethiopia [3, 7, 8].  
52 More than 390 million people are exposed to DENV each year resulting in 96 million annual  
53 cases of viral associated disease globally [9]. The World Health Organization (WHO) has  
54 reported 500,000 people develop severe disease each year, and about 1,250 die [10]. Although  
55 dengue has a global distribution, the majority of cases were from WHO South-East Asia region  
56 together with Western Pacific region bears nearly 75% of the global disease burden [11].  
57 Recently, there were few dengue infection reports in Ethiopia, specifically eastern parts of the  
58 country Dire Dawa and Somali regions [3, 8, 12]. Several factors are related to the increase of

59 dengue incidence in the Ethiopia. Among the most important ones are uncontrolled urbanization  
60 and absence of standardized public services such as water supply, sewage, and waste disposal  
61 [3].

62 Dengue virus infection produces a spectrum of clinical illness, ranging from an asymptomatic or  
63 mild febrile illness to classic DF to the most severe form of illness, dengue hemorrhagic fever  
64 (DHF) and dengue shock syndrome (DSS) [13]. DHF and DSS cases have also been increasingly  
65 recognized in South Asia, Latin America and the Pacific [14, 15], with pediatric cases being  
66 more common. Also DF and DHF/DSS have become more common in adults [16]. Dengue fever  
67 is clinically difficult to diagnose, especially in developing countries with no established dengue  
68 diagnostic techniques and could easily be mistaken for malaria, typhoid or unknown febrile  
69 illnesses [17]. The studies have reported that human antibody responses after dengue virus  
70 infection were highly cross-reactive with other arboviruses like Zika virus [18, 19].

71 Few studies of dengue infection have been carried out in Ethiopia; even though unknown causes  
72 of acute febrile illnesses are common. A confirmed DF case was reported for the first time in  
73 Ethiopia in Dire Dawa city in 2013 [8]. Later studies were conducted in somali region and north-  
74 western parts of the country [3, 12]. However, data are not available on the DF in Southern  
75 Ethiopia. Thus, the aim of this study was to generate baseline data on the prevalence of DF and  
76 associated risk factors in acute febrile patients in health facilities with catchments from the  
77 Borena Zone. This study will be helpful in providing information on DENV infection to  
78 healthcare authorities for better clinical management of patients and to design and implement  
79 appropriate control measures.

## 80 **Materials and Method**

### 81 **Ethical consideration**

82 Ethical clearance was obtained from the Institutional review board of Hawassa University  
83 College of Medicine and Health Sciences, Oromia Regional Health Bureau Ethics Review  
84 Committee and AHRI/ALERT Ethics Review Committee. Before data collection, patients were  
85 informed about the objective and purpose of the study, about their right not to participate on the  
86 study or withdraw at any point in time. Personal privacy and dignity was respected. Data was  
87 collected after obtaining participants'/guardians' informed written consent. Assent was also

88 sought in cases the study participants were children under 18 years old. All samples and forms  
89 containing patient information had no name or information that can identify a particular  
90 participant; and data was analyzed and interpreted in aggregate.

### 91 **Study Site, design, period and patient's characteristics**

92 A health facility based cross-sectional study was carried out from May to August 2016 in Borena  
93 Zone: Yabello Hospital, Moyale Hospital and Teltelle Health center. A Zone is located in  
94 southern part of Ethiopia, bordering Kenya. The climate of the area is arid; mean annual rain fall  
95 of 400-700 mm in two rainy seasons (spring and autumn), and mean annual temperature ranging  
96 from 25-37°C. The study population consisted of all consecutive patients presenting with acute  
97 febrile illness at the outpatient departments during the study period. The sample size was 519.

### 98 **Data collection and Laboratory test**

99 Data collectors interviewed the study participants using pretested structured questionnaire on  
100 socio-demographic and other risk factors such as use of bed net, trees around compound, use of  
101 mosquito repellent, presence of stagnant water around compound, and stay outside at night time.  
102 A 3-5 ml blood samples were collected, clotted and centrifuged at 1300r/minute. Separated sera  
103 were transported using liquid nitrogen (-170°C) to Hawassa University Referral Hospital, and  
104 stored in deep freezer (-80°C). Sera were transported using dry ice and screened at AHRI  
105 laboratory for DENV IgG and IgM using EUROIMMUN biochips indirect immunofluorescent  
106 assay (IIFA) kit (Medizinische Labordiagnostika AG-Germany) according to the manufacturer's  
107 manual [20].

### 108 **Data analysis**

109 Data was analyzed using SPSS version-20 window. Results were summarized using descriptive  
110 statistics and bivariate analysis. To control for possible effect of confounding, variables found to  
111 have an association with the outcome variable at P-value of 0.25 were entered into multivariable  
112 logistic regression model. Associations between independent and outcome variables were  
113 assessed and its strength was described using odds ratio with its 95% confidence intervals. P-  
114 value <0.05 was accepted as statistically significant.

## 115 **Results**

### 116 **Socio-demographic characteristics**

117 A total of 519 participants were investigated during the study period. Two hundred six (39.7%)  
118 of the study participants were from Teltelle health center, 36.6% were from Moyale hospital, and  
119 the remaining study participants (23.7%) were from Yabello hospital. The mean age of the  
120 participants was 25.5 years (range, 1 to 80 years, standard deviation 1.54), and those in the age  
121 range 15-29 years accounted 49.3%. Male participants accounted 51.3% with male to female  
122 ratio of 1:0.95. Substantial proportion of the study participants were rural residents (51.6%),  
123 illiterate (60.7%), and farmers by occupation (33.9%) (Table1).

### 124 **Seroprevalence of DENV infection**

125 The overall prevalence of exposure to DF was found to be 22.9% and 7.9% for IgG and IgM  
126 respectively. Male participants (67.2%) had higher rate of DENV IgG compared to females  
127 (32.8%). With respect to age, the prevalence of DENV IgG was highest (46.2%) in age group 15-  
128 29 years and lowest (11.8%) in age group greater than 45 years. Further, the rate of DENV  
129 infection IgG exposure was higher among urban residents (60.5%), animal keeper (22.7%) and,  
130 illiterate individuals (58.8%), and Teltelle health center (40.3%) (Table1). Overall, 20 of 119  
131 (48.8%) age group 15-29 years and 11 of 119 (26.8%) age group 1-14 years had IgM antibodies  
132 which suggest that recent infections with DENV were occurring (Table 3). In bivariate analysis,  
133 the association that yielded a p-value less than 0.25 with DENV IgG was gender and place of  
134 residence while age, study area, occupation and educational status of the study participants were  
135 not significantly associated. In multivariable logistic regression analysis male participants were  
136 at higher odds of having DENV IgG infection (AOR 2.68, 95% CI 1.66- 4.31) compared to  
137 females. Those study participants who lived in urban areas were 0.37 times (AOR = 0.37; 95%  
138 0.21-0.64) more likely to have anti-DENV IgG seropositivity than those who lived in rural areas  
139 (Table 1). The prevalence of DENV-3 IgG was highest (19.8%) and DENV-1 was lowest (8.3).  
140 Regarding IgM, both DENV-2 and DENV-3 were equally the highest (Table 2).

141

142

143

144

145

146 Table 1. Dengue virus IgG seropositivity relation to socio-demographic characteristics of  
147 respondents attending health facilities in Borena Zone, Southern Ethiopia, 2016

Characteristics	Number(%) tested	Number(%) positive	COR(95% CL)	AOR(95%CL)	P-value
<b>Sex</b>					
Male	266(51.3)	80(67.2)	2.36(1.53-3.63)*	2.68(1.66-4.31)**	0.00
Female	253(48.7)	39(32.8)	1	1	
<b>Age</b>					
1-14	103(19.8)	26(21.8)	1.13(0.54-2.36)		
15-29	256(49.3)	55(46.2)	0.92(0.47-1.79)		
30-45	99(19.1)	24(20.2)	1.07(0.51-2.28)		
>45	61(11.8)	14(11.8)	1		
<b>Residence</b>					
Rural	268(51.6)	47(39.5)	1	1	
Urban	251(48.4)	72(60.5)	1.89(1.25-2.87)*	0.37(0.21-0.64)**	0.001
<b>Education level</b>					
Illiterate	315(60.7)	70(58.8)	1.5(0.49-4.51)		
Primary	140(27)	34(28.6)	1.68(0.54-5.25)		
Secondary	39(7.5)	11(9.2)	2.06(0.57-7.39)		
College and above	25(4.8)	4(3.4)	1		
<b>Occupation</b>					
Farmer	176(33.9)	40(33.6)	0.76(0.29-1.94)		
Animal keeper	137(26.4)	27(22.7)	0.63(0.24-1.66)		
Employee	57(11)	10(8.4)	0.55(0.18-1.66)		
Student	67(12.9)	22(18.5)	1.26(0.46-3.46)		
House wife	57(11)	13(10.9)	0.76(0.26-2.22)		
Others	25(4.8)	7(5.9)	1		
<b>Study sites</b>					
Yabello	123(23.7)	33(27.7)	1		
Moyalle	190(36.6)	38(31.9)	0.68(0.40-1.16)		
Teltelle	206(39.7)	48(40.3)	0.83(0.49-1.38)		

148 NB: COR; Crude Odd Ratio AOR; Adjusted Odd Ratio Others: merchants, day laborer

149

150

151 **Table 2. Distribution of Dengue infection antibodies by serotypes**

	<b>IgG</b>	<b>IgM</b>
<b>Dengue virus serotypes</b>	<b>Pos No (%)</b>	<b>Pos No (%)</b>
DENV-1	43(8.3)	28(5.4)
DENV-2	71(13.7)	34(6.6)
DENV-3	103(19.8)	34(6.6)
DENV-4	66(12.7)	31(6)

152

153 Regarding the general awareness about DF, 38.2% of the participants had heard about this virus  
154 infection, and 9.6% responded DENV is transmitted by mosquito. Respondents were asked about  
155 the environmental exposures associated with mosquito-borne illnesses in their dwelling areas.  
156 Those who reported the existence of stagnant water and trees nearby their dwelling were 31.2%  
157 and 64.2%, respectively. Above 57% of respondents reported recent mosquito bites while they  
158 stayed outside during night time (47.8%). Three hundred thirty three (63.6%) of the study  
159 participants reported they slept under mosquito nets; of which 20.2 and 41.4% used bed net  
160 always and sometimes, respectively. However, only 4.1% used mosquito repellents on day or  
161 night time (Table 4).

162 The seropositivity of DENV IgG was 43.7% in those who heard about the virus and 13.4% in  
163 those who responded mosquito transmits the infection. The rate of exposure was observed 52.1%  
164 and 68.1% among those who responded they had a habit of staying outside during night and used  
165 bed net. A recent experience of having a mosquito bite (70.6%) was the only factor that  
166 significantly influenced the rate of DENV IgG exposure in bivariate analysis. However, use of  
167 mosquito repellent, awareness of DF, knowledge of transmission route, presence of tree around  
168 compound, habit of staying out side home in night time and a use of bed net were not  
169 significantly associated ( $p$ -value > 0.05). The association between recent mosquito bite and  
170 DENV IgG infection was found to be statistically significant in a multivariable logistic  
171 regression analysis (AOR=2.23; 95%CI, 1.39-3.56,  $p$ =0.001) (Table 4).

172

173

174 Table 3. Dengue virus IgM seropositivity relation to socio-demographic characteristics of  
 175 respondents attending health facilities in Borena Zone, Southern Ethiopia, 2016

<b>Characteristics</b>	<b>Number(%) tested</b>	<b>Number(%) positive</b>	<b>COR(95% CL)</b>	<b>AOR(95%CL)</b>	<b>P-value</b>
<b>Sex</b>					
Male	266(51.3)	16(39)	1		
Female	253(48.7)	25(61)	1.71(0.89-3.29)		
<b>Age</b>					
1-14	103(19.8)	11(26.8)	2.31(0.62-8.64)		
15-29	256(49.3)	20(48.8)	1.64(0.47-5.70)		
30-45	99(19.1)	7(17.1)	1.47(0.36-5.92)		
>45	61(11.8)	3(7.3)	1		
<b>Residence</b>					
Rural	268(51.6)	16(39)	1		
Urban	251(48.4)	25(61)	1.74(0.91-3.35)		
<b>Education level</b>					
Illiterate	315(60.7)	20(48.8)	0.49(0.14-1.80)		
Primary	140(27)	16(39)	0.95(0.25-3.52)		
Secondary	39(7.5)	2(4.9)	0.39(0.06-2.56)		
College and above	25(4.8)	3(7.3)	1		
<b>Occupation</b>					
Farmer	176(33.9)	10(24.4)	1.45(0.18-11.80)		
Animal keeper	137(26.4)	8(19.5)	1.49(0.18-12.45)		
Employee	57(11)	5(12.2)	2.31(0.26-20.84)		
Student	67(12.9)	10(24.4)	4.21(0.51-34.74)		
House wife	57(11)	7(17.1)	3.36(0.39-28.87)		
Others	25(4.8)	1(2.4)	1		
<b>Study sites</b>					
Yabello	123(23.7)	9(22)	1		
Moyalle	190(36.6)	14(34.1)	1.01(0.42-2.41)		
Teltelle	206(39.7)	18(43.9)	1.21(0.53-2.79)		

176 NB: COR; Crude Odd Ratio      AOR; Adjusted Odd Ratio      Others: merchants, day laborer

177

178



179 Table 4. Dengue virus IgG seropositivity relation to knowledge and environmental  
180 characteristics of respondents attending health facilities in Borena Zone, Southern Ethiopia, 2016

Characteristics	Number(%) tested	Number(%) positive	COR (95% CL)	AOR(95% CL)	P- value
<b>Heard about DF</b>					
Yes	198(38.2)	52(43.7)	1		
No	321(61.8)	67(56.3)	0.74(0.49-1.12)		
<b>Mode of transmission</b>					
Mosquito	50(9.6)	16(13.4)	1		
By blood	14(2.7)	5(4.2)	1.18(0.34-4.09)		
Do not know	455(87.8)	98(82.4)	0.58(0.31-1.10)		
<b>Stagnant water</b>					
Yes	162(31.2)	36(30.3)	1		
No	357(68.8)	83(69.7)	1.06(0.68-1.65)		
<b>Trees around compound</b>					
Yes	333(64.2)	80(67.2)	1.19(0.77-1.84)		
No	186(35.8)	39(32.8)	1		
<b>Stay outside at night</b>					
Yes	248(47.8)	62(52.1)	1.25(0.83-1.88)		
No	271(52.2)	57(47.9)	1		
<b>Recent mosquito bite</b>					
Yes	300(57.8)	84(70.6)	2.04(1.32-3.18)*	2.23(1.39-3.56)**	0.001
No	219(42.2)	35(29.4)	1	1	
<b>Bed net use</b>					
Yes	333(63.6)	81(68.1)	1		
No	186(36.4)	38(31.9)	1.25(0.81-1.94)		
<b>Repellent use</b>					
Yes	21(4.1)	6(5)	1		
No	498(95.9)	113(95)	0.73(0.28-1.94)		

181

182 NB: COR; Crude Odd Ratio      AOR; Adjusted Odd Ratio      Others: merchants, day laborer

183

184

## 185 Discussion

186 Recently, dengue fever infection has been considered an emerging public health problem in  
187 several African countries with risk of severe infections [21, 22]. Most febrile cases are routinely  
188 diagnosed and treated for typhoid and/or malaria without proper investigation for other  
189 conditions including viral infections. In Ethiopia where various mosquito-borne diseases are  
190 common, little is known about the epidemiology of arboviruses including DENV. However, the  
191 2013 and 2014 DF outbreaks in Dire Dawa and Godey [8, 12] that caused many morbidities and  
192 mortalities calls for systematic investigations to better describe the epidemiology of DF in  
193 various localities. Specially in relation to a worsening situation in climate change, which  
194 supports the emergence and re-emergence of vector-borne diseases, the need to have a strong  
195 surveillance system is critically important. This study assessed the prevalence of DENV  
196 infection and its associated risk factors in health facilities in Borena Zone where febrile illness is  
197 common.

198  
199 The seroprevalence of exposure to DENV IgG among febrile patients in the study area were  
200 22.9%. This result is in agreement with findings reported in Djibouti, 21.8% [23] and in  
201 Northern Province of Sudan, 24% [24]. However, the observed rate of DENV exposure was  
202 lower than results in Dire Dawa, 56.8% [8], northern Ethiopia, 33.3% [3], Eritrea, 33.3% [25],  
203 Kassala, Eastern Sudan, 71.7% [26], and El Gadarif state, Sudan, 47.6% [27]. In contrast, the  
204 prevalence of anti-DENV IgG exposure in this study was higher compared to the rates 7.7% and  
205 12.5% in Tanzania and Kenya respectively [28, 29]. These discrepancies may be due to  
206 difference in distribution of risk factors and variable climatic conditions by geographical regions,  
207 diversity of the studied populations, and difference in diagnostic performance of the employed  
208 laboratory methods. For example, some studies analyzed samples using laboratory techniques  
209 such as ELISA, PRNT and PCR which are more sensitive and specific compared to IIFA  
210 technique used in the current study. The high circulation of DENV in the study area could be  
211 attributed to several factors including misdiagnosis of febrile cases, the movement of migrants  
212 from endemic countries and the proliferation of breeding sites of *Aedes mosquitoes*. And also  
213 one-fourth of the study participants had antibody against DENV infection, dengue was under  
214 recognized and underreported in Ethiopia, which is in line with an earlier report in Africa [7].  
215 The overall prevalence of anti-DENV IgM seropositivity was 7.9% which indicates recent

216 infection with DENV. Since IgM against the DENV infection can be usually detected after the  
217 first 5-7 days of infection [30, 31]. However, the possibility that as the IgM antibodies remain  
218 negative for the first few days, and also the IgM reactivity was non-specific; thus there is cross-  
219 reactive due to infection with another flavivirus [32].

220 This study showed that gender significantly influenced the rate of anti-DENV IgG exposure  
221 status where male participants were disproportionally infected, which is in agreement with the  
222 study conducted elsewhere [3, 33]. It might be due to that males are more likely to work in  
223 outdoor forested areas where they come into contact with vectors for DENV. In this study, those  
224 individuals who were dwelling in urban areas were more affected than those in the rural areas.  
225 This is in agreement with the studies elsewhere [3, 34, 35]. It was previously reported that the  
226 seropositivity rate for DENV, which is carried by common vectors *Ae. aegypti* and *Ae.*  
227 *albopictus*, was higher in the geographically central sites (urban centers) than villages [36].  
228 Recent mosquito bite was significantly associated with anti-DENV IgG seropositivity. This is in  
229 line with the fact that mosquito bite exposes individuals to DF, and it may be the main mode of  
230 transmission in the study area. However, factors such as age, study site, occupation and  
231 educational status have little significance in influencing the rate of exposure to DENV in the  
232 current study.

233  
234 Although this is the first study of seroprevalence and risk factors associated with DENV  
235 infection in Southern Ethiopia, the study has several limitations. IIFA was shown to have good  
236 performance as compared PRNT; its inherent cross reactivity to other Flaviviruses could not be  
237 ruled out. Moreover, no febrile community controls or convalescent sera, and as any health  
238 institution based study that used consecutive volunteering cases only the risk of introducing bias  
239 is unavoidable. Thus, the findings of this study may not be generalized to the population in the  
240 study area.

241 In conclusion, this study showed low awareness among participants and the potential that DENV  
242 could likely be public health significance in the study area. Thus, we recommend a community  
243 based survey in the study and adjacent communities to verify our findings and take appropriate  
244 public health measures to provide potential outbreaks. Further systematic studies should be

245 conducted to determine the environmental, and host factors that determine the extent of exposure  
246 to DENV infection in the area for appropriate control and prevention planning.

## 247 **Abbreviation**

248 AHRI: Armauer Hansen research institute.

249 ELISA: Enzyme Immunosorbent assay

250 IIFA: Indirect Immunofluorescent Assay

251 IgG: Immunoglobulin G

252 IgM: Immunoglobulin M

253 PRNT: Plague Reduction Neutralization test

254 DF: Dengue fever

255 DENV: Dengue virus

256

## 257 **Acknowledgement**

258 I thank the Oromia Regional Health Bureau, health Bureaus and the responsible officials and  
259 professionals in the study area for their cooperation. I am also most grateful to the study  
260 participants for volunteering.

## 261 **References**

- 262 1. Yong YK, Thayan R, Chong HT, Tan CT, Sekaran SD. Rapid detection and serotyping of  
263 dengue virus by multiplex RT-PCR and real-time SYBR green RT-PCR. Singapore medical  
264 journal. 2007 Jul;48(7):662.
- 265 2. Dhar-Chowdhury P, Paul KK, Haque CE, Hossain S, Lindsay LR, Dibernardo A, et al.  
266 Dengue seroprevalence, seroconversion and risk factors in Dhaka, Bangladesh. PLoS  
267 neglected tropical diseases. 2017 Mar 23;11(3):e0005475.
- 268 3. Ferede G, Tiruneh M, Abate E, Wondimeneh Y, Dامتie D, Gadisa E, et al. A serologic  
269 study of dengue in northwest Ethiopia: Suggesting preventive and control measures. PLoS  
270 neglected tropical diseases. 2018 May 31;12(5):e0006430.
- 271 4. Stramer SL. The potential threat to blood transfusion safety of emerging infectious disease  
272 agents. Clinical Advances Hematology and Oncology. 2015; 13:420–2.
- 273 5. Weerakkody RM, Palangasinghe DR, Dalpatadu KP, Rankothkumbura JP, Cassim MR,  
274 Karunanayake P. Dengue fever in a liver-transplanted patient: a case report. Journal of  
275 medical case reports. 2014;8(1):378.
- 276 6. Kyle J, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008;  
277 62:71–92. <https://doi.org/10.1146/annurev.micro.62.081307.163005> PMID: 18429680

- 278 7. Ananda A, Joel N, Kuritsky G, William L, Harold S, Margolis H. Dengue virus infection in  
279 Africa. *Emerg Infect Dis*. 2011; 17:1349–54 <https://doi.org/10.3201/eid1708.101515> PMID:  
280 21801609
- 281 8. Abyot BW, Mesfin M, Wubayehu K, Esayas K, Milliyon W, Abiy G, et al. The first acute  
282 febrile illness investigation associated with dengue fever in Ethiopia, 2013: A descriptive  
283 analysis. *Ethiop J Health Dev*. 2014; 28:155–61.
- 284 9. Guzman MG, Harris E (2015) Dengue. *The Lancet* 385: 453–465.
- 285 10. World Health Organization (WHO) Global strategy for dengue prevention and control 2012–  
286 2020. Geneva, Switzerland: World Health Organization, 2012.
- 287 11. WHO-TDR. Dengue: guidelines for diagnosis, treatment, prevention, and control- New  
288 Edition. Geneva, Switzerland. World Health Organization. 2009
- 289 12. Yusuf MA, Ali AS. Epidemiology of Dengue Fever in Ethiopian Somali Region:  
290 Retrospective Health Facility-Based Study. *CAJPH*. 2016; 2:51–6.
- 291 13. Martina BE, Koraka P, Osterhaus A (2009). Dengue virus pathogenesis, an integrated view.  
292 *Clin. Microbiol. Rev.*, 22: 564–581.
- 293 14. Gupta N, Srivastava S, Jain A, Chaturvedi UC. Dengue in India. *Indian J Med Res* 2012;  
294 136:373– 390.PMID:23041731
- 295 15. Humayoun MA, Waseem T, Jawa AA, Hashmi MS, Akram J. Multiple dengue serotypes and  
296 high frequency of dengue hemorrhagic fever at two tertiary care hospitals in Lahore during  
297 the 2008 dengue virus outbreak in Punjab, Pakistan. *International Journal of Infectious*  
298 *Diseases*. 2010;14:e54-9.
- 299 16. Teixeira MG, Costa MC, Coelho G, Barreto ML. Recent shift in age pattern of dengue  
300 hemorrhagic fever, Brazil. *Emerging infectious diseases*. 2008;14(10):1663-.
- 301 17. Baba M, Saron MF, Vorndam A, Adeniji J, Diop O, Olaleye D. Dengue virus infections in  
302 patients suspected of malaria/typhoid in Nigeria. *J Am Sci*. 2009;5(5):129–134.
- 303 18. Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, et al.  
304 Human antibody responses after dengue virus infection are highly cross-reactive to Zika  
305 virus. *Proc Natl Acad Sci U S A*. 2016;113:7852–7.
- 306 19. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda  
307 T,etal. Dengue virus sero-cross-reactivity drives antibody dependent enhancement of  
308 infection with zika virus. *Nat Immunol*. 2016;17:1102–8.
- 309 20. EUROIMMUN AG. Biochips mosaics and profile for detection of Flavivirus infections  
310 instructions for indirect immunoflourescent test, 2013.
- 311 21. Amarasinghe A, Kuritsk JN, Letson GW, Margolis HS. Dengue virus infection in Africa.  
312 *Emerg Infect Dis*. 2011;17(8):1349–1354.
- 313 22. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in  
314 Southeast Asia. *PLoS Negl Trop Dis*. 2013;7(2): e2055
- 315 23. Andayi F, Charrel R, Kieffer A, Richet H, Pastorino B, Leparc I. A Sero-epidemiological  
316 Study of Arboviral Fevers in Djibouti, Horn of Africa. *PLoS Negl Trop Dis*. 2014; 8:e3299.  
317 <https://doi.org/10.1371/journal.pntd.0003299> PMID: 2550269

- 318 24. Watts D, El-Tigani A, Botros B, Salib A, Olmn J, McCarthy M. Arthropod-borne viral  
319 infections associated with a fever outbreak in the northern province of Sudan. *J Trop Med*  
320 *Hyg.* 1994; 97:228–30. PMID: 8064945
- 321 25. Abdulmumini U, Jacob D, Diana R, Araia B, Yohannes G, Goitom M, et al. Dengue fever  
322 outbreaks in Eritrea, 2005–2015. A case for strengthening surveillance, control, and  
323 reporting. *Glob Health Res Policy.* 2016; 1:17. <https://doi.org/10.1186/s41256-016-0016-5>  
324 PMID: 29202065
- 325 26. Tajeldin A, AbdelAziem A, Mubarak K, Ishag A. Epidemiology of Dengue Infections in  
326 Kassala, Eastern Sudan. *J Med Virol.* 2012; 84:500–3. <https://doi.org/10.1002/jmv.23218>  
327 PMID: 22246838
- 328 27. Eldigail MH, Adam GK, Babiker RA, Khalid F, Adam IA, Omer OH, Ahmed ME, Birair SL,  
329 Haroun EM, AbuAisha H, Karrar AE. Prevalence of dengue fever virus antibodies and  
330 associated risk factors among residents of El-Gadarif state, Sudan. *BMC public health.* 2018  
331 Dec;18(1):921.
- 332 28. Francesco V, Emanuele N, Silvia M, Monica S, Maria G, Nazario B, et al. Seroprevalence of  
333 dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island,  
334 Zanzibar. *Int J Infect Dis.* 2012; 16:e44–e6. <https://doi.org/10.1016/j.ijid.2011.09.018> PMID:  
335 22088862
- 336 29. Caroline O, Petronella A, Aymond N, Stella G, Cyrus W. Seroprevalence of Infections with  
337 Dengue, Rift Valley Fever and Chikungunya Viruses in Kenya. *PLoS One.* 2015;  
338 10:e0132645. <https://doi.org/10.1371/journal.pone.0132645> PMID: 26177451
- 339 30. Maria G, Scott B, Harvey A, Philippe B, Jeremy F, Duane J, et al. Dengue: a continuing  
340 global threat. *Nat Rev Microbiol.* 2010; 8:S7–S16. <https://doi.org/10.1038/nrmicro2460>  
341 PMID: 21079655
- 342 31. Madara AA, Abdulraheem NO. Relative abundance of adult mosquitoes in University of  
343 Abuja Main Campus, Abuja FCT, Nigeria. *Nig J Parasitol.* 2013;34(2):1–5.
- 344 32. Calisher C, Karabatsos N, Dalrymple J, Shope R, Porterfield J, Westaway E, et al. Antigenic  
345 relationships between flaviviruses as determined by cross-neutralization tests with polyclonal  
346 antisera. *J Gen Virol.* 1989; 70:37–43.
- 347 33. Yik W, Tun Y, Li W, Lee C, Grace Y, Lyn J, et al. Seroepidemiology of Dengue Virus  
348 Infection Among Adults in Singapore. *Ann Acad Med Singapore.* 2009; 38:667–75. PMID:  
349 19736569
- 350 34. Mohammed S, Syed M, Omrana P, Syed A, Mubarak K, Mutasim E, et al. Dengue fever in a  
351 border state between Sudan and Republic of South Sudan: Epidemiological Perspectives. *J*  
352 *Public Health Epidemiol.* 2013; 5:319–24. 56.
- 353 35. Sadia N, Muhammad A, Muhammad A, Ahmad R, Bahar M. The epidemiology of dengue  
354 fever in district Faisalabad, Pakistan. *Int J Sci Res.* 2015; 5
- 355 36. Gubler D. Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st)  
356 Century. *Trop Med Health.* 2011; 39:3–11.

357

358 **Supporting information**

359 S1 STROBE Checklist. (DOC)